{"id":384678,"date":"2020-11-19T03:42:03","date_gmt":"2020-11-19T08:42:03","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=384678"},"modified":"2020-11-19T03:42:03","modified_gmt":"2020-11-19T08:42:03","slug":"neodynamics-ab-publ-third-quarter-2020","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/neodynamics-ab-publ-third-quarter-2020\/","title":{"rendered":"NeoDynamics AB (publ) Third Quarter 2020"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"xn-location\">STOCKHOLM<\/span>, <span class=\"xn-chron\">Nov. 19, 2020<\/span> \/PRNewswire\/ &#8212; <b>The proposed financing strengthens NeoDynamics ahead of pivotal period<\/b><\/p>\n<p>\n        <b>Third quarter 2020\u00a0<\/b>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 <\/p>\n<ul type=\"disc\">\n<li>There were no sales during the period. Revenue amounted to <span class=\"xn-money\">SEK 2.643 m<\/span> (<span class=\"xn-money\">4.581 m<\/span>) including capitalized costs of <span class=\"xn-money\">SEK 2.051 m<\/span> (<span class=\"xn-money\">4.469 m<\/span>).\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 <\/li>\n<li>Loss after tax amounted to <span class=\"xn-money\">SEK -6.731 m<\/span> (<span class=\"xn-money\">-4.416 m<\/span>).\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 <\/li>\n<li>Loss per share amounted to <span class=\"xn-money\">SEK -0.19<\/span> (-0.29).<\/li>\n<\/ul>\n<p>\n        <b>9 months 2020\u00a0<\/b>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 <\/p>\n<ul type=\"disc\">\n<li>There were no sales during the period. Revenue amounted to <span class=\"xn-money\">SEK 15.175 m<\/span> (<span class=\"xn-money\">16.329 m<\/span>), whereof capitalized costs <span class=\"xn-money\">SEK 14.140 m<\/span> (16 <span class=\"xn-money\">214 m<\/span>).\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 <\/li>\n<li>Costs for product development contuned to be higher than expected.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 <\/li>\n<li>Loss after tax amounted to <span class=\"xn-money\">SEK -18.011 m<\/span> (<span class=\"xn-money\">-12.498 m<\/span>).\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 <\/li>\n<li>Loss per share amounted to <span class=\"xn-money\">SEK -0.71<\/span> (-0.82).\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 <\/li>\n<li>Equity per share was\u00a0 <span class=\"xn-money\">SEK 2.52<\/span> (3.63 at year-end).\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 <\/li>\n<li>Equity ratio was 94 (60 per cent at year-end)<\/li>\n<\/ul>\n<p>\n        <b>Significant events during the third quarter\u00a0<\/b>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 <\/p>\n<ul type=\"disc\">\n<li>Reference centers established in <span class=\"xn-location\">Germany<\/span> to support the introduction of the new pulse biopsy system NeoNavia and optimize the diagnosis of breast cancer. <\/li>\n<li>An Extraordinary General Meeting on 13 August resolved on an incentive program for employees with a maximum of 1,021,900 warrants, where each warrant entitles to subscribe to one new share at <span class=\"xn-money\">SEK 4.71<\/span> per share during the period 1 Aug &#8211; <span class=\"xn-chron\">30 Sep 2023<\/span>. <\/li>\n<li>The directed share issue of 2,561,339 shares, <span class=\"xn-money\">SEK 7,684,017<\/span> announced in April, was registered with the Swedish Companies Registration Office in September. Hence, the share capital is <span class=\"xn-money\">SEK 3,600,695.10<\/span> distributed on 36,006,951 shares. <\/li>\n<li>In September, the NeoNavia biopsy system was very well received at the international senology congresses in <span class=\"xn-location\">Vienna<\/span> and Lucerne, and for the first time, physicians gained practical experience of the finished product.<\/li>\n<\/ul>\n<p>\n        <b>Significant events after the period\u00a0<\/b>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 <\/p>\n<ul type=\"disc\">\n<li>An Extraordinary General Meeting on <span class=\"xn-chron\">November 19<\/span> will resolve on a directed share issue to a limited group of investors. The subscription price in the share issue is proposed to be <span class=\"xn-money\">SEK 3.71<\/span> per share and was determined through an accelerated bookbuilding procedure. The share issue can provide the company with close to <span class=\"xn-money\">SEK 90 million<\/span> before transaction costs. <\/li>\n<li>On <span class=\"xn-chron\">November 2<\/span>, the company announced that its CFO, J\u00f6rgen Vrenning, has decided to leave the company after eight years to retire. J\u00f6rgen will continue in an advisory role until the end of <span class=\"xn-chron\">May 2021<\/span> to ensure a smooth transition. <\/li>\n<li>The company joined a scientific partnership to evaluate the NeoNavia pulse biopsy system for knee and bone tissue sampling in a new potential indication, osteoarthritis. <\/li>\n<li>Neodynamics gets first order for the pulse biopsy system NeoNavia from the Buckinghamshire Healthcare NHS Trust, <span class=\"xn-location\">London<\/span>.<\/li>\n<\/ul>\n<p>\n        <b>CEO&#8217;s comments<\/b>\n      <\/p>\n<p>\n        <b>Proposed new financing strengthens NeoDynamics ahead of pivotal period<\/b>\n      <\/p>\n<p>During the autumn, the Board discussed various ways to strengthen the company&#8217;s cash flow in order to be able to carry out the forthcoming market introduction of NeoNavia in a successful manner. These discussions, which have also involved the company&#8217;s main owners, led to the Board&#8217;s proposal for a directed issue of approximately <span class=\"xn-money\">SEK 90 million<\/span>. The company&#8217;s owners will decide on the matter at an extraordinary general meeting on 19 November. The share issue provides much-needed room for manoeuvre to create value. The Board&#8217;s assessment is that the funding benefits both old and new shareholders.Through the proposed raising of capital, the ownership circle will be expanded with competence and experience in MedTech, a significant stamp of quality for a company such as NeoDynamics The Dutch investment firm Nyenburgh and Swedish Cardeon Futuring Finance have thoroughly analysed the company prior to investing in NeoDynamics. Both appreciate the solid preparation for the launch of NeoNavia, and state it as one of the most important reasons why they have chosen to invest in NeoDynamics. <\/p>\n<p>\n        <b>First order<\/b>\n      <\/p>\n<p>NeoNavia is now launched in the UK, <span class=\"xn-location\">Germany<\/span> and <span class=\"xn-location\">Sweden<\/span>, somewhat delayed compared to plan as the announced product development dragged on and the pandemic further delayed the project in the critical verification and validation phase. Covid-19 currently also limits the possibility of physical meetings on site with radiologists, but many activities are now underway thanks to our specialist sales staff in the UK, <span class=\"xn-location\">Germany<\/span> and Sweden.It is gratifying to note that after a short introduction, the first centre in the UK was able to place an order. A strong symbolism that we are now up and running. Other centres will want to follow suit.The cancer area remains a priority in hospitals and there is a backlog when it comes to caring for breast cancer patients. Our studies have familiarized doctors with our product and built knowledge on how to use it. This provides benefits when NeoNavia now becomes commercially available.Due to the pandemic, the study in the UK has not been able to be conducted normally and therefore we are expanding with more centres for faster results that can be used in sales work.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 <\/p>\n<p>\n        <b><br \/>\n          <span class=\"xn-location\">The United States<\/span> is the next step<\/b>\n      <\/p>\n<p>Work on our registration application to the Federal Drug Administration (FDA) is ongoing, as is the dialogue with the authority. We expect to submit the documentation at the beginning of 2021, in order to get the go-ahead to start selling NeoNavia in the <span class=\"xn-location\">USA<\/span> during the year as well. Covid-19 has led to the closure of several states where we have planned user tests with American physiciansThe work in the <span class=\"xn-location\">USA<\/span> also lays the foundation for the regulative application in <span class=\"xn-location\">China<\/span>, which is next on the agenda. We will also perform a local study in <span class=\"xn-location\">China<\/span> to get a strong basis, both in the dialogue with the authority and with future customers in the Chinese market.<\/p>\n<p>\n        <b>Scale up of production<\/b>\n      <\/p>\n<p>The company works continuously to optimize its production processes to keep manufacturing costs at a level that enables a long-term good profit margin. We have been collaborating for just over a year with a well-established FDA-approved Thai manufacturer who, together with us, is preparing the transfer of our disposable probes (needles) to serial \/ commercial production. The first delivery is expected to take place in mid-2021. Until then, the company&#8217;s Swedish partner Sanmina in \u00d6rnsk\u00f6ldsvik will be used, which will continue to manufacture the reusable system parts (base unit and driver) which are built with a significantly larger technical content.Finally, we have recently started an international research collaboration to evaluate the NeoNavia pulse biopsy system for knee and bone tissue sampling in osteoarthritis, which is also a large indication. Here we collaborate with William Hunter Revisited, a research consortium consisting of six universities as well as academic hospitals, which specialize in osteoarthritis. We know that our pulse technology is attractive to develop in other indications as well, which we have confirmed by being approached by this research team <\/p>\n<p>NeoDynamics is finally on its way to the market. We look forward to in-depth relationships with cancer clinics in <span class=\"xn-location\">Europe<\/span>, to roll out NeoNavia in the US and to receive feedback on how the products will be received by doctors and patients.<\/p>\n<p>\n        <i><br \/>\n          <b>CEO <span class=\"xn-person\">Anna Eriksrud<\/span><\/b><br \/>\n        <\/i>\n      <\/p>\n<p>\n        <i>The information was submitted for publication through the agency of the contact person set out below, at <span class=\"xn-chron\">08:55 CET<\/span> on <span class=\"xn-chron\">November 19, 2020<\/span><\/i>\n      <\/p>\n<p>\n        <b>For additional information please contact:<\/b>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 <\/p>\n<p>\n        <span class=\"xn-person\">Anna Eriksrud<\/span>, CEO NeoDynamics AB (publ). Phone +46\u00a0708\u00a0444\u00a0966, e-mail: <a target=\"_blank\" href=\"mailto:anna.eriksrud@neodynamics.com\" rel=\"nofollow noopener noreferrer\">anna.eriksrud@neodynamics.com<\/a><\/p>\n<p>\n        <u>J\u00f6rgen Vrenning, CFO\/IR NeoDynamics AB (publ), Phone +46 708 519 648, e-mail: <\/u><br \/>\n        <a target=\"_blank\" href=\"mailto:jorgen.vrenning@neodynamics.com\" rel=\"nofollow noopener noreferrer\">jorgen.vrenning@neodynamics.com<\/a>\n      <\/p>\n<p>\n        <b>About NeoDynamics<\/b>\n      <\/p>\n<p>NeoDynamics AB (publ) is a Swedish Medical Technology Company dedicated to advancing diagnosis and care of breast cancer. The company has developed an innovative biopsy system, NeoNavia. The pulse biopsy system is built on a patented pulse technology, based on research at the <span class=\"xn-org\">Karolinska Institutet<\/span> in <span class=\"xn-location\">Sweden<\/span>. The system is designed to offer clinicians and patients accurate lesion targeting and high tissue yield for correct diagnosis and individualized treatment. NeoNavia is evaluated at leading clinics in UK, <span class=\"xn-location\">Germany<\/span> and <span class=\"xn-location\">Sweden<\/span>. <\/p>\n<p>\n        <b>About NeoNavia<\/b>\n      <\/p>\n<p>NeoNavia is the brand name for the entire pulse biopsy system intended to be used under ultrasound guidance.\u00a0 NeoNavia consists of a base unit, a handheld driver and three different types of biopsy needles. Each needle type is driven by a pulse technology enabling high precision and control when inserting and positioning the biopsy needle in a suspicious lesion. The system is designed to offer accurate lesion targeting and high tissue yield for correct diagnosis and individualized treatment.<\/p>\n<p>\n        <b>About the pulse technology<\/b>\n      <\/p>\n<p>The patented pulse technology is based on a pneumatically driven mechanism that enables high precision and control when inserting and positioning the biopsy needle, independent of tissue type, size and location. The pneumatic driver that generates the pulses is placed in a handheld instrument. With power from the base-unit, the driver accelerates the needle with great control even over a short distance, enabling its distinct stepwise insertion without the risk of destroying surrounding tissue. This facilitates ease of access and flexibility in sampling, even in very small lesions in delicate and difficult locations.<\/p>\n<p>This information was brought to you by Cision <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=2987789-1&amp;h=1893822492&amp;u=http%3A%2F%2Fnews.cision.com%2F&amp;a=http%3A%2F%2Fnews.cision.com\" rel=\"nofollow noopener noreferrer\">http:\/\/news.cision.com<\/a><\/p>\n<p>\n        <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=2987789-1&amp;h=1842663363&amp;u=https%3A%2F%2Fnews.cision.com%2Fneodynamics%2Fr%2Fneodynamics-ab--publ--third-quarter-2020%2Cc3239987&amp;a=https%3A%2F%2Fnews.cision.com%2Fneodynamics%2Fr%2Fneodynamics-ab--publ--third-quarter-2020%2Cc3239987\" rel=\"nofollow noopener noreferrer\">https:\/\/news.cision.com\/neodynamics\/r\/neodynamics-ab&#8211;publ&#8211;third-quarter-2020,c3239987<\/a>\n      <\/p>\n<p>The following files are available for download:<\/p>\n<div>\n<table cellspacing=\"0\" cellpadding=\"0\" border=\"0\" class=\"prnsbt1 prnsbr1 prnsbb1 prnsbl1\">\n<tr>\n<td class=\"prngen2\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=2987789-1&amp;h=2079121781&amp;u=https%3A%2F%2Fmb.cision.com%2FMain%2F17640%2F3239987%2F1337201.pdf&amp;a=https%3A%2F%2Fmb.cision.com%2FMain%2F17640%2F3239987%2F1337201.pdf\" class=\"prnews_a\" rel=\"nofollow noopener noreferrer\">https:\/\/mb.cision.com\/Main\/17640\/3239987\/1337201.pdf<\/a><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen2\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">Release<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<\/table><\/div>\n<p>\u00a0<\/p>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO97887&amp;sd=2020-11-19\" \/> View original content:<a id=\"PRNURL\" rel=\"nofollow\" href=\"http:\/\/www.prnewswire.com\/news-releases\/neodynamics-ab-publ-third-quarter-2020-301176812.html\">http:\/\/www.prnewswire.com\/news-releases\/neodynamics-ab-publ-third-quarter-2020-301176812.html<\/a><\/p>\n<p>SOURCE  NeoDynamics<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=IO97887&amp;Transmission_Id=202011190338PR_NEWS_USPR_____IO97887&amp;DateId=20201119\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire STOCKHOLM, Nov. 19, 2020 \/PRNewswire\/ &#8212; The proposed financing strengthens NeoDynamics ahead of pivotal period Third quarter 2020\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 There were no sales during the period. Revenue amounted to SEK 2.643 m (4.581 m) including capitalized costs of SEK 2.051 m (4.469 m).\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Loss after tax amounted to SEK -6.731 m (-4.416 m).\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Loss per share amounted to SEK -0.19 (-0.29). 9 months 2020\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 There were no sales during the period. Revenue amounted to SEK 15.175 m (16.329 m), whereof capitalized costs SEK 14.140 m (16 214 m).\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Costs for product development contuned to be higher than expected.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Loss after tax amounted to SEK -18.011 m (-12.498 m).\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Loss per share amounted to SEK -0.71 (-0.82).\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Equity per share &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/neodynamics-ab-publ-third-quarter-2020\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;NeoDynamics AB (publ) Third Quarter 2020&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-384678","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>NeoDynamics AB (publ) Third Quarter 2020 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/neodynamics-ab-publ-third-quarter-2020\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NeoDynamics AB (publ) Third Quarter 2020 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire STOCKHOLM, Nov. 19, 2020 \/PRNewswire\/ &#8212; The proposed financing strengthens NeoDynamics ahead of pivotal period Third quarter 2020\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 There were no sales during the period. Revenue amounted to SEK 2.643 m (4.581 m) including capitalized costs of SEK 2.051 m (4.469 m).\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Loss after tax amounted to SEK -6.731 m (-4.416 m).\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Loss per share amounted to SEK -0.19 (-0.29). 9 months 2020\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 There were no sales during the period. Revenue amounted to SEK 15.175 m (16.329 m), whereof capitalized costs SEK 14.140 m (16 214 m).\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Costs for product development contuned to be higher than expected.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Loss after tax amounted to SEK -18.011 m (-12.498 m).\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Loss per share amounted to SEK -0.71 (-0.82).\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Equity per share &hellip; Continue reading &quot;NeoDynamics AB (publ) Third Quarter 2020&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/neodynamics-ab-publ-third-quarter-2020\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-19T08:42:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO97887&amp;sd=2020-11-19\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neodynamics-ab-publ-third-quarter-2020\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neodynamics-ab-publ-third-quarter-2020\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"NeoDynamics AB (publ) Third Quarter 2020\",\"datePublished\":\"2020-11-19T08:42:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neodynamics-ab-publ-third-quarter-2020\\\/\"},\"wordCount\":1472,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neodynamics-ab-publ-third-quarter-2020\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=IO97887&amp;sd=2020-11-19\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neodynamics-ab-publ-third-quarter-2020\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neodynamics-ab-publ-third-quarter-2020\\\/\",\"name\":\"NeoDynamics AB (publ) Third Quarter 2020 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neodynamics-ab-publ-third-quarter-2020\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neodynamics-ab-publ-third-quarter-2020\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=IO97887&amp;sd=2020-11-19\",\"datePublished\":\"2020-11-19T08:42:03+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neodynamics-ab-publ-third-quarter-2020\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neodynamics-ab-publ-third-quarter-2020\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neodynamics-ab-publ-third-quarter-2020\\\/#primaryimage\",\"url\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=IO97887&amp;sd=2020-11-19\",\"contentUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=IO97887&amp;sd=2020-11-19\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neodynamics-ab-publ-third-quarter-2020\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NeoDynamics AB (publ) Third Quarter 2020\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"NeoDynamics AB (publ) Third Quarter 2020 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/neodynamics-ab-publ-third-quarter-2020\/","og_locale":"en_US","og_type":"article","og_title":"NeoDynamics AB (publ) Third Quarter 2020 - Market Newsdesk","og_description":"PR Newswire STOCKHOLM, Nov. 19, 2020 \/PRNewswire\/ &#8212; The proposed financing strengthens NeoDynamics ahead of pivotal period Third quarter 2020\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 There were no sales during the period. Revenue amounted to SEK 2.643 m (4.581 m) including capitalized costs of SEK 2.051 m (4.469 m).\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Loss after tax amounted to SEK -6.731 m (-4.416 m).\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Loss per share amounted to SEK -0.19 (-0.29). 9 months 2020\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 There were no sales during the period. Revenue amounted to SEK 15.175 m (16.329 m), whereof capitalized costs SEK 14.140 m (16 214 m).\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Costs for product development contuned to be higher than expected.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Loss after tax amounted to SEK -18.011 m (-12.498 m).\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Loss per share amounted to SEK -0.71 (-0.82).\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Equity per share &hellip; Continue reading \"NeoDynamics AB (publ) Third Quarter 2020\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/neodynamics-ab-publ-third-quarter-2020\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-19T08:42:03+00:00","og_image":[{"url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO97887&amp;sd=2020-11-19","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neodynamics-ab-publ-third-quarter-2020\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neodynamics-ab-publ-third-quarter-2020\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"NeoDynamics AB (publ) Third Quarter 2020","datePublished":"2020-11-19T08:42:03+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neodynamics-ab-publ-third-quarter-2020\/"},"wordCount":1472,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neodynamics-ab-publ-third-quarter-2020\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO97887&amp;sd=2020-11-19","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neodynamics-ab-publ-third-quarter-2020\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/neodynamics-ab-publ-third-quarter-2020\/","name":"NeoDynamics AB (publ) Third Quarter 2020 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neodynamics-ab-publ-third-quarter-2020\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neodynamics-ab-publ-third-quarter-2020\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO97887&amp;sd=2020-11-19","datePublished":"2020-11-19T08:42:03+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neodynamics-ab-publ-third-quarter-2020\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/neodynamics-ab-publ-third-quarter-2020\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neodynamics-ab-publ-third-quarter-2020\/#primaryimage","url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO97887&amp;sd=2020-11-19","contentUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO97887&amp;sd=2020-11-19"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neodynamics-ab-publ-third-quarter-2020\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"NeoDynamics AB (publ) Third Quarter 2020"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/384678","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=384678"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/384678\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=384678"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=384678"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=384678"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}